Fosun Pharma 复星医药
17 significant filings since 30 May 2026: 2 on share pledge, 5 on guarantee or financial assistance and 4 on pledge released, and 4 other kinds. The latest, on 24 Sep 2026: 复星医药关于控股子公司签订合作与许可协议的公告.
自 30 May 2026 起有 17 份重大公告：share pledge 2 份、guarantee or financial assistance 5 份、pledge released 4 份，另有 4 类。最新一份（24 Sep 2026）：复星医药关于控股子公司签订合作与许可协议的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 0 brokers | 0 brokers |
| 7 days ago | 0 brokers | 0 brokers |
| 30 days ago | 0 brokers | 0 brokers |
| 60 days ago | 0 brokers | 0 brokers |
| 90 days ago | 0 brokers | 0 brokers |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
| Year | Filed | Consensus | Brokers 券商 | Reported 实际 | Surprise 偏差 |
|---|---|---|---|---|---|
| FY2019 | 31 Mar 2020 | 1.60 | 3 | 1.30 | -18.8% |
Surprise is reported EPS against the consensus on the day before the annual report was filed. 偏差为实际每股收益与年报披露前一日一致预期之差。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0.